ReviewInternational journal of molecular sciences2014
Brain metastasis-initiating cells: survival of the fittest.
Review in International journal of molecular sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Epithelial-mesenchymal transition and sunitinib resistance in renal cell carcinoma: mechanisms and therapeutic strategies.Frontiers in pharmacology · 2026Review
- Peripheral blood tumor marker levels can indicate the location of lung cancer metastasis.Oncology letters · 2025Article
- Anti-metastatic potential of flavonoids for the treatment of cancers: focus on epithelial-mesenchymal transition (EMT) process.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- De novo GTP synthesis is a metabolic vulnerability for the interception of brain metastases.Cell reports. Medicine · 2024Article
- SRRM4-mediated REST to REST4 dysregulation promotes tumor growth and neural adaptation in breast cancer leading to brain metastasis.Neuro-oncology · 2024Article
- A Nomogram Based on Clinicopathological Characteristics for Estimating the Risk of Brain Metastasis from Advanced Gastric Cancer: A Multi-Center Retrospective Clinical Study.Therapeutics and clinical risk management · 2024Article
- The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis.Journal of hematology & oncology · 2022Review
- Low and steady wins the race: For melanoma brain metastases, is prevention better than a cure?Neuro-oncology · 2022Article
- Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases.Molecular brain · 2021Article
- Cancer Cell Dormancy in Metastasis.Cold Spring Harbor perspectives in medicine · 2020Review
- PFND1 Predicts Poor Prognosis of Gastric Cancer and Promotes Cell Metastasis by Activating the Wnt/β-Catenin Pathway.OncoTargets and therapy · 2020Article
- Boost Irradiation Integrated to Whole Brain Radiotherapy in the Management of Brain Metastases.Pathology oncology research : POR · 2020Article
- Correlation of Leukocyte Subtypes, Neutrohyl Lymphocyte Ratio, and Functional Outcome in Brain Metastasis.Open access Macedonian journal of medical sciences · 2018Article
- Comprehensive molecular biomarker identification in breast cancer brain metastases.Journal of translational medicine · 2017Article
- Preclinical Modeling and Therapeutic Avenues for Cancer Metastasis to the Central Nervous System.Frontiers in oncology · 2017Review
- Microarray expression profiling identifies genes, including cytokines, and biofunctions, as diapedesis, associated with a brain metastasis from a papillary thyroid carcinoma.American journal of cancer research · 2016Article
- Article
- A Quantitative System for Studying Metastasis Using Transparent Zebrafish.Cancer research · 2015Article
- Evolution of multidisciplinary brain metastasis management: case study and literature review.The Yale journal of biology and medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Brain metastases (BMs) are the most common brain tumor in adults, developing in about 10% of adult cancer patients. It is not the incidence of BM that is alarming, but the poor patient prognosis. Even with aggressive treatments, median patient survival is only months. Despite the high rate of BM-associated mortality, very little research is conducted in this area. Lack of research and staggeringly low patient survival is indicative that a novel approach to BMs and their treatment is needed. The ability of a small subset of primary tumor cells to produce macrometastases is reminiscent of brain tumor-initiating cells (BTICs) or cancer stem cells (CSCs) hypothesized to form primary brain tumors. BTICs are considered stem cell-like due to their self-renewal and differentiation properties. Similar to the subset of cells forming metastases, BTICs are most often a rare subpopulation. Based on the functional definition of a TIC, cells capable of forming a BM could be considered to be brain metastasis-initiating cells (BMICs). These putative BMICs would not only have the ability to initiate tumor growth in a secondary niche, but also the machinery to escape the primary tumor, migrate through the circulation, and invade the neural niche.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.